PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3140856

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MASATOSHI USHIODA	08/26/2014
KUNIO KOBAYASHI	08/26/2014
DAISUKE SAITO	08/26/2014
SHOGO SAKUMA	08/26/2014
TOSHIYASU IMAI	08/26/2014
KAZUHIDE INOUE	09/02/2014

RECEIVING PARTY DATA

Name:	NIPPON CHEMIPHAR CO., LTD	
Street Address:	2-3, IWAMOTO-CHO 2-CHOME, CHIYODA-KU	
City:	TOKYO	
State/Country:	JAPAN	
Postal Code:	101-0032	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14371868

CORRESPONDENCE DATA

Fax Number: (703)716-1180

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7037161191

Email: gbpatent@gbpatent.com

GREENBLUM AND BERNSTEIN, P.L.C. Correspondent Name:

Address Line 1: 1950 ROLAND CLARKE PLACE

Address Line 4: RESTON, VIRGINIA 20191

ATTORNEY DOCKET NUMBER:	P46184
NAME OF SUBMITTER:	SEAN MYERS-PAYNE
SIGNATURE:	/Sean Myers-Payne/
DATE SIGNED:	12/10/2014

Total Attachments: 8

source=P46184_Dec_Assignment#page1.tif

REEL: 034457 FRAME: 0770 503094250

PATENT



P46184 Page 1

COMBINED INVENTOR'S DECLARATION AND ASSIGNMENT

DECLARATION

The herein-identified application was made or authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization to Permit Access to Application by Participating Office

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the herein-identified patent application is filed access to the herein-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the herein-identified patent application is filed to have access to the herein-identified patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the herein-identified patent application with respect to: 1) the herein-identified patent application-as-filed; 2) any foreign application to which the herein-identified patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the herein-identified patent application; and 3) any U.S. application-as-filed from which benefit is sought in the herein-identified patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices.

The undersigned hereby authorizes the U.S. attorney or agent appointed herein to accept and follow instructions from either his foreign patent agent or corporate representative, if any, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned.

Direct Correspondence to: CUSTOMER NUMBER 07055

At: Greenblum & Bernstein, P.L.C. 1950 Roland Clarke Place Reston, VA 20191

Direct Telephone Calls to: Greenblum & Bernstein, P.L.C. (703) 716-1191

P46184 Page 2

ASSIGNMENT

WHEREAS, Masatoshi USHIODA, a resident of Tokyo, Japan, whose mailing address is c/o Nippon Chemiphar Co., Ltd., Discovery Reserach Laboratories, 1-22, Hikokawado, Misato-shi, Saitama 341-0005 JAPAN, Kunio KOBAYASHI, a resident of Saitama, Japan, whose mailing address is c/o Nippon Chemiphar Co., Ltd., Discovery Reserach Laboratories, 1-22, Hikokawado, Misato-shi, Saitama 341-0005 JAPAN, Daisuke SAITO, a resident of Tokyo, Japan, whose mailing address is c/o Nippon Chemiphar Co., Ltd., Discovery Reserach Laboratories, 1-22, Hikokawado, Misato-shi, Saitama 341-0005 JAPAN, Shogo SAKUMA, a resident of Saitama, Japan, whose mailing address is c/o Nippon Chemiphar Co., Ltd., Discovery Reserach Laboratories, 1-22, Hikokawado, Misato-shi, Saitama 341-0005 JAPAN, Toshiyasu IMAI, a resident of Tokyo, Japan, whose mailing address is c/o Nippon Chemiphar Co., Ltd., Discovery Reserach Laboratories, 1-22, Hikokawado, Misato-shi, Saitama 341-0005 JAPAN, and Kazuhide INOUE, a resident of Fukuoka, Japan, whose mailing address is c/o Kyushu University, 6-10-1, Hakozaki, Higashi-ku, Fukuoka-shi, Fukuoka 812-8581 JAPAN, hereinafter referred to as the ASSIGNORS, have invented a certain improvement relating to

P2X4 RECEPTOR ANTAGONIST

for which an application for Letters Patent in the United States entered the National Stage in the United States Patent and Trademark Office on July 11, 2014 and was awarded Application No. 14/371,868, and which Application is a National Stage of International Application No. PCT/JP2013/050320, filed January 10, 2013.

AND WHEREAS, **Nippon Chemiphar Co., Ltd,** a corporation organized and existing under the laws of JAPAN, whose mailing address is 2-3, Iwamoto-cho 2-chome, Chiyoda-ku, Tokyo 101-0032 JAPAN, hereinafter known as the ASSIGNEE, is desirous of acquiring the entire right, title and interest for the United States in and to said invention and application, including any and all divisions and continuations thereof, and any and all Letters Patent which may be granted thereon, including any and all renewals, reissues, reexaminations, and prolongations thereof.

NOW, THIS WITNESSETH that for good and valuable consideration, the receipt whereof is hereby acknowledged, said ASSIGNORS hereby assign, sell and transfer to said ASSIGNEE, its assigns and legal representatives, the entire and exclusive right, title and interest in and to said invention and application, for the United States including any and all divisions and continuations thereof, and any and all Letters Patent which may be granted therefor and all rights to sue for past and future infringement thereunder, said ASSIGNEE and its assigns and legal representatives to have, hold, exercise and enjoy the said invention and application, including any and all divisions and continuations thereof, and any and all Letters Patent which may be granted thereon, including any and all renewals, reissues, reexaminations, and prolongations thereof, with all the rights, powers, privileges, and advantages in any ways arising from or pertaining thereto, for and during the term or terms of any and all such Letters Patent when granted, including any and all renewals, reissues, reexaminations, and prolongations thereof, for the use and benefit of said ASSIGNEE and its assigns and legal representatives in as ample and beneficial a manner to all intents and purposes as the said ASSIGNORS might or could have held and enjoyed the same, if this assignment had not been made.

{P46184 02129103.DOC}

as the said ASSIGNORS might or could have held and enjoyed the same, if this assignment had not been made.

AND said ASSIGNORS hereby agree to execute all papers necessary to file applications in the United States for said invention and to assign the same to said ASSIGNEE, or any assignee acquiring title to said invention, and to execute any other papers that may be needed in connection with filing said application and securing Letters Patent thereon.

AND said ASSIGNORS authorize and request the Commissioner of Patents to issue Letters Patent on said application, and on any and all divisions and continuations thereof, to said ASSIGNEE, its assigns and legal representatives, in accordance herewith.

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

Shinichi chiqusa (Name)

August 26, 20/4
(Date)

Masatoshi Ushioda

Masatoshi USHIODA

26/August/2014

Date

Second Witness (Optional):

(Name)

Angust 26, 2014

(Date)

First Witness (Optional):

Shinichi Chiguse
(Name)

August 26, 3014
(Date)

26/August/2014 Date

Second Witness (Optional):

(Name)

August 26, 2014
(Date)

First Witness (Optional):

Shinich chiquen (Name)

Dagust 26, 201X

Daisake Saite

Daisuke SAITO

26/ August /2014

Second Witness (Optional):

(Name)

August 26, 2014

(Date)

First Witness (Optional):

Shirich chigusi
(Name)

Dugant 26, 2014
(Date)

Shogo-Sakuma.
Shogo SAKUMA

26/August/2014

Date

Second Witness (Optional):

(Name)

Angust 26, 2014

First Witness (Optional):

Shimich Chiquen
(Name)

Aggust 26, 2014
(Date)

Second Witness (Optional):

First Witness (Optional):

Shinichi Chiquer
(Name)

September 2, 20/4
(Date)

September 2, 2014

Second Witness (Optional):

Toshika Jata
(Name)

September 2, 2014
(Date)